Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

COMISAIR: CGM ‘Makes the Difference’ in Type 1 Diabetes

Key clinical point: How patients with type 1 diabetes monitor their glucose is more important than how insulin is delivered.

Major finding: End-of-study hemoglobin A1c values were significantly lower, compared with baseline values, in patients with type 1 diabetes using real-time continuous glucose monitoring with multiple daily injections of insulin (7.0% [53 mmol/mol], P = .0002) or an insulin pump (6.9% [52 mmol/mol], P less than .0001) than those who used self-monitoring of blood glucose with multiple daily injections (8.0% [64 mmol/mol], P = .3574) or an insulin pump (7.7% [61 mmol/mol], P = .1).

Study details: A 3-year follow-up of the COMISAIR study, a prospective, real-world clinical trial with 94 patients with type 1 diabetes who used either multiple daily injections of insulin or an insulin pump with either real-time continuous glucose monitoring or self-monitoring of blood glucose.

Disclosures: The study was supported by the Agency for Healthcare Research and the Ministry of Health of the Czech Republic. Dr. Šoupal reported receiving honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, and Roche. Dexcom also paid for the development of the manuscript published in Diabetes Care.

Citation:

Šoupal J et al. EASD 2019, Abstract 40; Šoupal J et al. Diabetes Care. 2019 Sep 17. doi: 10.2337/dc19-0888.